Personalized treatments – Phosphoproteomics research reveals new avenues for developing targeted therapies for patients with pancreatic cancer
- Post by: OPL
- October 3, 2023
- Comments off
In our recent study pubished in Cell Reports, PhD student Andrea Valles shows how profile-guided phosphoproteomics can be used to select low dose combination treatment based on three kinase inhibitors. Kinase activity ranking of individual cell lines using our INKA pipeline, provided the rationale for a combination of within pathway and parallel pathway targeting with triple drug combos that were able to combat the difficult to treat pancreatic cancer cells in vitro and in vivo.
For more information and link to the paper, see: